Sanofi, Regeneron Seek Fast-Track Reviews From EMA
Speedy Evaluations Requested For Avalglucosidase Alfa And Evinacumab
EU sponsors of two investigational drugs – one to treat the rare genetic Pompe disease and the other for patients with severe inherited form of high cholesterol – have requested a speedy review of their respective marketing applications.
